par Metzger-Filho, Otto;Moulin, Camilo;Awada, Ahmad 
Référence Current Clinical Pharmacology, 5, 3, page (166-177)
Publication Publié, 2010-08

Référence Current Clinical Pharmacology, 5, 3, page (166-177)
Publication Publié, 2010-08
Article révisé par les pairs
Titre: |
|
Auteur: | Metzger-Filho, Otto; Moulin, Camilo; Awada, Ahmad |
Informations sur la publication: | Current Clinical Pharmacology, 5, 3, page (166-177) |
Statut de publication: | Publié, 2010-08 |
Sujet CREF: | Cancérologie |
Mots-clés: | Breast cancer |
Colorectal cancer | |
Lung cancer | |
Resistance | |
Targeted therapy | |
Therapy individualization | |
MeSH keywords: | Antineoplastic Agents -- administration & dosage -- therapeutic use |
Drug Delivery Systems | |
Drug Resistance, Neoplasm | |
Forecasting | |
Humans | |
Individualized Medicine -- trends | |
Molecular Targeted Therapy -- trends | |
Neoplasms -- drug therapy | |
Receptor, Epidermal Growth Factor -- antagonists & inhibitors -- metabolism | |
TOR Serine-Threonine Kinases -- antagonists & inhibitors -- metabolism | |
Note générale: | Journal Article |
Review | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:1574-8847 |
info:doi/10.2174/157488410791498716 | |
info:pii/BSP/CCP/E-Pub/0011 | |
info:scp/78649344228 | |
info:pmid/20406173 |